Reuters logo
BRIEF-Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​
September 1, 2017 / 9:02 PM / 19 days ago

BRIEF-Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​

Sept 1 (Reuters) - Keryx Biopharmaceuticals Inc

* Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​

* Keryx Biopharma - new ‍product agreement is in addition to two agreements entered under master agreement for Patheon’s manufacture of Auryxia tablets​

* Keryx Biopharmaceuticals Inc - ‍product agreement has an initial term ending December 31, 2024​

* Keryx Biopharmaceuticals Inc - ‍ also product agreement will automatically renew after initial term for successive terms of two years each​ Source text: [bit.ly/2wqOvJz] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below